Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 94.68% is 102% above its 5-year average of 46.95%, near the high end of its 5-year range (-9883.00%–100.00%).
65.88% above its 12-month average of 57.08%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
94.68%
GROSS MARGIN AVG TTM
57.08%
GROSS MARGIN AVG 3Y
66.13%
GROSS MARGIN AVG 5Y
46.95%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+65.88%
CURRENT VS 3Y AVG
+43.18%
CURRENT VS 5Y AVG
+101.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+129.78%
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$218.30M
Gross Margin
94.68%
TTM Avg
57.08%
3Y Avg
66.13%
5Y Avg
46.95%
Market Cap
$216.91M
Gross Margin
85.91%
TTM Avg
92.95%
3Y Avg
46.48%
5Y Avg
30.98%
Market Cap
$220.93M
Gross Margin
71.79%
TTM Avg
68.33%
3Y Avg
60.69%
5Y Avg
55.54%
Market Cap
$215.07M
Gross Margin
87.24%
TTM Avg
79.57%
3Y Avg
65.64%
5Y Avg
63.99%
Market Cap
$214.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$214.24M
Gross Margin
64.24%
TTM Avg
63.06%
3Y Avg
61.57%
5Y Avg
61.22%
Market Cap
$225.24M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$210.98M
Gross Margin
-31952.78%
TTM Avg
-15926.39%
3Y Avg
-7913.19%
5Y Avg
-5242.13%
Market Cap
$210.41M
Gross Margin
83.89%
TTM Avg
91.94%
3Y Avg
70.97%
5Y Avg
47.31%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $218.30M | 94.68% | 57.08% | 66.13% | 46.95% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 85.91% | 92.95% | 46.48% | 30.98% |
| Profound Medical Corp. (PROF)vs › | $220.93M | 71.79% | 68.33% | 60.69% | 55.54% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 87.24% | 79.57% | 65.64% | 63.99% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 64.24% | 63.06% | 61.57% | 61.22% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -31952.78% | -15926.39% | -7913.19% | -5242.13% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 83.89% | 91.94% | 70.97% | 47.31% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 86.89% | 79.42% | 84.96% | 87.58% |
Gross Margin
94.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | -9.81% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 97.23% |
| 2025-06-30 | 97.96% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 89.09% |
| 2024-09-30 | 19.07% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | -6787.50% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 98.49% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | -9883.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | -65.20% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
